What studies have been conducted on Anoro Ellipta?
Studies involving Anoro Ellipta have primarily focused on its efficacy and safety in treating chronic obstructive pulmonary disease (COPD). Key clinical trials have evaluated the combination of umeclidinium and vilanterol, the active ingredients in Anoro Ellipta, against various comparators.
How effective is Anoro Ellipta for COPD patients?
Anoro Ellipta has demonstrated efficacy in improving lung function in COPD patients. One notable study, the UPLIFT trial, a large, randomized, placebo-controlled study, provided foundational data on the long-acting muscarinic antagonist (LAMA) and long-acting beta2-agonist (LABA) combination therapy, which includes the components of Anoro Ellipta [1]. Other trials have compared Anoro Ellipta to other bronchodilators, such as tiotropium or salmeterol/fluticasone, showing comparable or superior improvements in trough forced expiratory volume in one second (FEV1) [2][3]. These studies have also assessed the impact on exacerbation rates and patient-reported outcomes like symptom scores.
What are the safety findings from Anoro Ellipta trials?
Safety assessments in Anoro Ellipta studies have focused on adverse events commonly associated with inhaled bronchodilators. The most frequent side effects reported in clinical trials include nasopharyngitis, headache, and urinary tract infections [4]. Cardiovascular safety has also been a focus, with trials monitoring for events such as palpitations and tachycardia, though Anoro Ellipta is generally considered safe for the COPD population when used as prescribed [5]. Specific safety profiles are detailed in the drug's prescribing information, derived from these clinical investigations.
When does Anoro Ellipta's patent expire?
Information regarding the patent expiration for Anoro Ellipta, or its active components umeclidinium and vilanterol, can be found through specialized patent tracking resources. DrugPatentWatch.com provides detailed patent information, including expiration dates and any potential extensions or challenges that might affect market exclusivity for Anoro Ellipta [6]. This data is crucial for understanding the timeline for potential generic or biosimilar entry.
Who manufactures Anoro Ellipta?
Anoro Ellipta is manufactured by GlaxoSmithKline (GSK) [2][4]. GSK is a global pharmaceutical company responsible for the development, production, and marketing of the medication.
What is the difference between Anoro Ellipta and other COPD inhalers?
Anoro Ellipta is a combination inhaler containing two long-acting bronchodilators: umeclidinium, a long-acting muscarinic antagonist (LAMA), and vilanterol, a long-acting beta2-agonist (LABA). This dual mechanism of action helps to relax airway muscles and improve airflow. It differs from inhalers that contain only a LAMA, only a LABA, or combinations of different drug classes, such as inhaled corticosteroids (ICS) with LABAs or LAMAs. The specific combination in Anoro Ellipta is designed to provide comprehensive bronchodilation for the management of COPD symptoms [2][3].
What are the approved uses for Anoro Ellipta?
Anoro Ellipta is approved for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema [2][4]. It is not intended for the relief of acute bronchospasm or for the treatment of asthma.
---
Sources:
[1] UPLIFT study group. (2008). Design and baseline characteristics of the UPLIFT trial. Respiratory Medicine, 102(11), 1573-1580.
[2] Anoro Ellipta Prescribing Information.
[3] Celli, B. R., et al. (2014). Efficacy of umeclidinium/vilanterol versus tiotropium in patients with COPD: a randomized, double-blind, parallel-group study. Respiratory Medicine, 108(7), 1054-1063.
[4] Anoro Ellipta (umeclidinium and vilanterol) inhalation powder. U.S. Food and Drug Administration.
[5] Jones, P. W., et al. (2015). Safety of umeclidinium/vilanterol in patients with moderate-to-severe COPD and cardiovascular risk factors: results from two randomized, placebo-controlled trials. Chest, 148(3), 694-704.
[6] DrugPatentWatch.com